Phaseline

Targets › SERPINA1

SERPINA1 (Alpha-1-antitrypsin): drug programs, companies and trials

8 programs from 8 companies in 10 trials: 5 Phase 1, 4 Phase 3, 1 Phase 2; Metabolic and endocrine, Infectious disease, Respiratory; next expected readout Dec 2026.

Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. (UniProt, P01009)

Open in Phaseline: the race on SERPINA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Grifols TherapeuticsAlpha-1 15% (DRUG): Alpha1-Proteinase Inhibitor Subcutaneous (Human), 15%
Protease inhibitor replacement therapy - recombinant alpha-1 antitrypsin (AAT) replacement
SERPINA1Phase 3Alpha 1 Antitrypsin DeficiencySep 2027
TakedaFazirsiran
Z-AAT reducing agent; inhibits expression of Z-AAT protein
SERPINA1Phase 3Alpha1-Antitrypsin DeficiencyAug 2028
Medical University InnsbruckAlfa1 Antitrypsin
Serine protease inhibitor; suppresses neutrophil elastase and reduces inflammation
SERPINA1Phase 2Alcohol-Associated HepatitisDec 2026
Krystal BiotechKB408
Replication-defective HSV-1 vector expressing full-length human SERPINA1
SERPINA1Phase 1Alpha 1-Antitrypsin DeficiencyDec 2026
Wave Life Sciences USAWVE-006
RNA editing oligonucleotide to correct alpha-1 antitrypsin deficiency
SERPINA1Phase 1Alpha-1 Antitrypsin DeficiencySep 2027
Weill Medical College of Cornell UniversityAAV8hAAT(AVL)
AAV8-delivered alpha-1 antitrypsin (oxidation-resistant variant) gene therapy
SERPINA1Phase 1Alpha 1-Antitrypsin DeficiencyApr 2028
Beam TherapeuticsBEAM-302
lipid nanoparticle (LNP)-based alpha-1 antitrypsin (AAT) gene therapy
SERPINA1Phase 1Alpha 1-Antitrypsin DeficiencyMay 2028
Tessera TherapeuticsTSRA-196
In-vivo genome editing via lipid nanoparticles to increase alpha-1 antitrypsin expression
SERPINA1Phase 1Alpha-1 Antitrypsin Deficiency (AATD)Mar 2029

Conditions

Alpha 1-Antitrypsin Deficiency (3) Alpha1-Antitrypsin Deficiency (3) Alpha-1 Antitrypsin Deficiency (AATD) (1) Alpha-1 Antitrypsin Deficiency (1) Alcohol-Associated Hepatitis (1) Alpha 1 Antitrypsin Deficiency (1)

Modalities

small molecule (6), other (2)

Companies

Krystal Biotech (1) Takeda (1) Weill Medical College of Cornell University (1) Tessera Therapeutics (1) Wave Life Sciences USA (1) Beam Therapeutics (1) Medical University Innsbruck (1) Grifols Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.